Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of MDR-TB Treatment Regimen Based on Pyrazinamide Susceptibility
NCT02120638Phase 3Unknown
- Sponsor
- Huashan Hospital
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pyrazinamide in multidrug-resistant tuberculosis (MDR-TB), sponsored by Huashan Hospital. Status: unknown.
02
Drugs
pyrazinamide
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT02120638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120638.